Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

The efficacy was far lower against the South African variant, though.

Novavax Coronavirus Vaccine Candidate Shows 96% Efficacy With Original Strain, 86% Against U.K. Variant

Novavax, Inc (NASDAQ: NVAX) shares spiked nearly 32% in the after-hours and regular session on Thursday. What Happened: The Maryland-based biotechnology company said Thursday that its COVID-19 vaccine, NVX-CoV2373, was 96.4% effective “against mild, moderate and severe disease caused by the original COVID-19 strain” in Phase 3 trials.

Why Novavax Shares Spiked 32% Today

Novavax Inc. NVAX shares rallied in the extended session Thursday after the biotech drug maker said studies show its COVID-19 vaccine is highly effective. Novavax shares surged 17% after hours, following an 8.8% gain to close the regular session at $187.63.

Novavax stock rallies on COVID-19 vaccine study results

- 100% protection against severe disease - Final analysis in U.K. trial confirms 96% efficacy against original strain of COVID-19 - Efficacy against variants confirmed in U.K. and South Africa GAITHERSBURG, Md., March 11, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced final efficacy of 96.4% against mild, moderate and severe disease caused by the original COVID-19 strain in a pivotal Phase 3 trial in the United Kingdom (U.K.) of NVX–CoV2373, the company's vaccine candidate.

Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials

AMC Entertainment

GameStop

The recent mega-cap stocks sell-off was bizarre and painful to Nasdaq stocks. But it is already paying rewards to those who stepped up.

These 3 Mega-Cap Stocks Got Too Cheap for No Good Reason

It's shifting from an unprofitable biotech to a company collecting billions in revenue.

What Are Novavax's Long-Term Prospects?

NVAX's quarterly revenue rose over 75% Q/Q. COVID-19 supply spurred growth. Regulatory approval for a vaccine may not happen until Q2. It could take a few more months to build out manufacturing capabilities.

Novavax: Uncertain COVID-19 Vaccine Approval Triggers Violent Sell-Off

Datadog

Plug Power

Zoom Video

Wall Street professionals are counting on these popular growth stocks to bounce back.

4 Beaten-Down Nasdaq Stocks With 57% to 78% Upside, According to Wall Street

This biotech stock looks like a better buy now than it did a few weeks ago.

3 Reasons to Buy Novavax Stock After Its Huge Pullback

AbbVie

Bristol-Myers

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The biotech industry seems poised for further growth due to factors like advancements in drug research and faster regulatory process, making it wise to look at names like AbbVie (ABBV) and Novavax (NVAX)

5 Stocks to Watch Amid Continued Expansion in the Biotech Industry

There isn't much juice left in this coronavirus vaccine drugmaker's stock.

Could Novavax Be a Millionaire-Maker Stock?

This Warning From the CEO of the World's Biggest Vaccine Maker Could Be Bad News for Novavax

Here's Why the Novavax CEO is Shrugging Off Moderna's and Pfizer's Market Dominance

GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the H.C. Wainwright Virtual Global Life Sciences conference. Novavax' COVID-19 vaccine candidate, NVX-CoV2373, will be the topic of discussion.

Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat

Moderna

Pfizer

AstraZeneca

BioNTech SE

CureVac B.V

Johnson & Johnson

Sinovac Biotech

The companies in line for the biggest gains – and the shareholders who have already made fortunes

From Pfizer to Moderna: who's making billions from Covid-19 vaccines?

Ocugen, Inc.

Vaxart

And let's take a look at the most overrated, the most promising, and the most under-the-radar coronavirus stocks too.

This Is the Cheapest Coronavirus Vaccine Stock Right Now

Novavax stock (NASDAQ: NVAX) dropped 15% over the last five trading days and has underperformed the S&P 500 which remained almost flat over the same period. The stock is also down by almost 22% over the last ten trading days.

Will The Sell Off In Novavax Stock Continue?

Palantir Technologies

Riot Blockchain

These companies used to be flying high, but fortunes can change quickly on Wall Street. Now they're stocks that could crash soon.

4 Stocks That Could Crash Soon

They're key as its coronavirus vaccine candidate approaches possible commercialization.

These 2 Elements in Novavax's Earnings Report Could Mean Billions for the Biotech

Poland-based biotech firm Mabion has signed a preliminary agreement to manufacture Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine, reports Bloomberg. The polish company will get 40 million zlotys ($11 million) in loans and equity from a state-run fund to support doubling its production capacity in Poland.

Novavax Partners With Poland's Mabion For COVID-19 Vaccine Production: Bloomberg

Only details about the diversity of participants have been released at this point.

Novavax's COVID Vaccine Trial: Are There Any Yellow Flags So Far?

Novavax's (NVAX) fourth-quarter 2020 loss is wider than estimates. Sales beat the same.

Novavax (NVAX) Loss Widens in Q4, Revenues Top Estimates

Hint: It wasn't the biotech's all-time best top line or the all-time worst bottom line.

What Really Mattered With Novavax's Q4 Update

Novavax CEO Stanley Erck has predicted the company's coronavirus vaccine could be authorized in the US as early as May. Trial results suggest the vaccine is highly effective, though less so against the variant first found in South Africa, which has spread to at least 10 US states including New York.

Novavax's COVID-19 vaccine could be authorized as early as May, its CEO said. A trial suggests it is 89% effective, although slightly less so against contagious variants.

Stanley Erck said his company will have at least tens of millions of doses available if and when it's granted authorization.

News for Novavax Stock (NVAX)